Ratcliffe Liam 4

What Happened

• Liam Ratcliffe, a director of OnKure Therapeutics, was granted derivative awards covering 15,300 shares on 2026-03-31. The award price is $0.00 (no cash paid at grant), and the filing classifies this as an award/grant (Code A). This is a compensation grant that vests over time rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-31; Form 4 filed 2026-04-01.
• Award: derivative securities for 15,300 shares at $0.00.
• Vesting: 1/36th of the shares vest on April 30, 2026 and then on the last day of each month thereafter (36-month monthly vesting), contingent on continued service (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Filed on 2026-04-01 for a 2026-03-31 grant — appears timely (no late filing flag shown).
• No exercise, sale, tax-withholding, or cash transfer reported in this transaction.

Context

• This was a time‑based equity award (derivative), meaning Ratcliffe gains rights to underlying shares as they vest; until vested and converted (if required), they are not outright shares he can freely sell. Such grants are common as director/executive compensation and signal alignment with long‑term performance, but they are not the same signal as an outright purchase of stock.